ARTICLE | Clinical News
Darleukin: Phase III started
February 8, 2016 8:00 AM UTC
Philogen began an open-label, international Phase III trial to evaluate 13 million international units (MIU) of intralesional L19-IL2 in combination with 400 ug intralesional L19-TNF given weekly for...